(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 20 October 2015 - Actelion Ltd (SIX: ATLN) today announced its results for the first nine months of 2015. OPERATING HIGHLIGHTS Opsumit (macitentan) - continues strong launch trajectory Opsumit (macitentan) - commercially available in over 30 countries including Japan Selexipag (Uptravi®) - regulatory procedures on track Specialty pipeline - strengthens as several promising compounds advance FINANCIAL HIGHLIGHTS Product sales of CHF 1,522 million - strong growth driven by Opsumit uptake of CHF 354 million Core earnings of CHF 651 million - increased operational leverage 2015 financial guidance upgrade: Crossing the 20% mark for core...
↧